## Resnick, Josephine

From:Resnick, JosephineSent:Tuesday, October 26, 2021 9:24 AMTo:'Michelle Olsen'; Kulinski, JosephCc:Agnihothram, SudhakarSubject:RE: [EXTERNAL] RE: STN 125752: Information Request #12

Dear Dr. Olsen,

Please find below a clarified request:

Please submit a sensitivity analysis for the rates of solicited adverse reactions by including all relevant events (occurring within the 7 days post vaccination) reported in the COVID-19 symptom logs from subjects that were ultimately negative for SARS-CoV-2. Please perform a similar sensitivity analysis for unsolicited AEs for those events reported in the COVID-19 symptom logs from subjects that were ultimately negative for SARS-CoV-2 but which are not included in the first sensitivity analysis for solicited reactions.

Let us know if you have any additional questions regarding this request.

Warm regards,

Jo Resnick

From: Michelle Olsen <Michelle.Olsen@modernatx.com> Sent: Monday, October 25, 2021 4:10 PM To: Kulinski, Joseph <Joseph.Kulinski@fda.hhs.gov> Cc: Resnick, Josephine <Josephine.Resnick@fda.hhs.gov>; Agnihothram, Sudhakar <Sudhakar.Agnihothram@fda.hhs.gov> Subject: [EXTERNAL] RE: STN 125752: Information Request #12

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Dr. Kulinski,

We are currently having a team meeting to discuss the below IR#12 and we have a few different interpretations of the question that could lead to different answers. If you could request a follow-up clarification from the review team, we'd appreciate it:

The Sponsor would like to ask for further clarifications on the reviewers' request on "including all relevant events (occurring within the 7 days post vaccination) from the e-diary captured as COVID-19 symptoms that were negative for SARS-CoV-2". Are the reviewers referring to the "Symptom Log" reported by participants? Is the request for sensitivity analysis of SAR(solicited adverse reactions), to include the following symptoms reported on "Symptom Log" within 7 days post vaccination in those participants reported such symptoms on "Symptom Log" and later had a negative RT-PCR result? Symptoms reported on "Symptom Log":

- Fever based on Temperature reported

- Chills
- Fatigue
- Muscle Aches (Myalgia) or Body Aches
- Headache
- Nausea or Vomiting

If the team could please re-state the question keeping in mind our questions above, we would greatly appreciate that.

Best regards,

Michelle

From: Kulinski, Joseph <<u>Joseph.Kulinski@fda.hhs.gov</u>> Sent: Friday, October 22, 2021 5:13 PM To: Michelle Olsen <<u>Michelle.Olsen@modernatx.com</u>> Cc: Resnick, Josephine <<u>Josephine.Resnick@fda.hhs.gov</u>>; Agnihothram, Sudhakar <<u>Sudhakar.Agnihothram@fda.hhs.gov</u>> Subject: STN 125752: Information Request #12

EXTERNAL

Dear Dr. Olsen,

Our review of your August 24, 2021 submission (STN 125752) is ongoing. Please find attached an information request regarding clinical dataset analyses.

Please acknowledge receipt of this email and let me know if you have any questions.

Best,

Joe Kulinski

Joseph Kulinski, PhD Biologist/Primary Reviewer

Center for Biologics Evaluation and Research Office of Vaccines Research and Review U.S. Food and Drug Administration Tel: 301-796-2640 Josephine.Resnick@fda.hhs.gov





THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

## □ Please consider the environment before printing this email

Confidentiality notice and disclaimer: The information in this message and any attachments is intended for the exclusive use of the addressee(s), is confidential and may be privileged or otherwise protected from disclosure. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, of any such information by persons or entities other than the intended addressee(s) is prohibited. If you have received this message in error and are not the intended addressee, please notify the sender immediately and delete this message and any attachments from your system without reading or disclosing them. If you are not the intended addressee, be advised that any use of the information in this message and any attachment is prohibited and may be unlawful, and you must not copy this message or attachment or disclose the contents to any other person.